The Effect of the drug Tirzepatide compared with the drug Dulaglutide onthe Cardiovascular Risk in Patients with Type 2 Diabetes
- Conditions
- Type 2 diabetes mellitusTherapeutic area: Diseases [C] - Hormonal diseases [C19]
- Registration Number
- EUCTR2019-002735-28-RO
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 12500
[1] Men or women at least 40 years old with a diagnosis of T2DM (WHO
2019).
[2] Established CVD, including at least 1 of the following (a-c):
a. Coronary artery disease (CAD) with EITHER of the following:
- Documented history of spontaneous MI
- =50% stenosis in 1 or more major coronary arteries, determined by
invasive angiography
- =50% stenosis in 2 or more major coronary arteries, determined by
computed tomography coronary angiography (CTCA), or
- History of surgical or percutaneous coronary revascularization
procedure;
b. Cerebrovascular disease – ANY of the following:
- Documented history of ischemic stroke
- Carotid arterial disease with =50% stenosis, documented by carotid
ultrasound, magnetic resonance imaging (MRI), or angiography
- Carotid stenting or surgical revascularization;
c. Peripheral arterial disease with EITHER of the following:
- Intermittent claudication and ankle-brachial index <0.9
- Prior nontraumatic amputation or peripheral vascular procedure (eg,
stenting or surgical revascularization), due to peripheral arterial
ischemia.
[3] HbA1c =7% (=53 mmol/mol) and =10.5% (=91.3 mmol/mol) based
on central laboratory assessment at screening.
[4] Body mass index (BMI) =25 kg/m2.
[5] At the time of signing the informed consent: Contraceptive use by
men or women should be consistent with local regulations regarding the
methods of contraception for those participating in clinical trials.
[6] In the investigator's opinion, patients are well motivated, capable,
and willing to learn how to self-inject treatment (tirzepatide or
dulaglutide), as required for this protocol (visually impaired persons
and/or persons with physical limitations who are not able to perform the
injections must have the assistance of an individual trained to inject the
study drug).
[7] Patients are capable of giving signed informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 6250
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6250
[8] Have type 1 diabetes mellitus.
[9] Have uncontrolled diabetes requiring immediate therapy (such as
diabetic ketoacidosis) at screening or randomization, in the judgment of
the physician.
[10] Have had 1 or more events of severe hypoglycemia and/or 1 or
more events of hypoglycemia unawareness within 6 months prior to
screening.
[11] Have a history of proliferative retinopathy or macular edema. A
dilated fundoscopic exam, evaluated by an eye care professional
(ophthalmologist or optometrist) is required to confirm eligibility. In
addition, nonproliferative diabetic retinopathy that requires acute
treatment according to the opinion of the investigator is also excluded.
[12] Have been hospitalized for CHF within 2 months prior to screening.
[13] Have chronic New York Heart Association Functional Classification
IV CHF.
[14] Are currently planning a coronary, carotid, or peripheral artery
revascularization.
[15] Had chronic or acute pancreatitis any time prior to screening,
irrespective of etiology.
[16] Have a known clinically significant gastric emptying abnormality
(eg, severe diabetic gastroparesis or gastric outlet obstruction), have
undergone gastric bypass (bariatric) surgery or restrictive bariatric
surgery (eg, Lap-Band®, vertical sleeve gastrectomy), or chronically
take drugs that directly affect GI motility.
[17] Have acute or chronic hepatitis, signs or symptoms of any other
liver disease, or an alanine aminotransferase (ALT) level =3X the upper
limit of normal (ULN) for the reference range, as determined by the
central laboratory.
[18] Have known chronic severe renal failure (defined as a known eGFR
<15 mL/minute/1.73 m2) or are on chronic dialysis.
[19] Have evidence of a significant, uncontrolled endocrine abnormality
(eg, thyrotoxicosis or adrenal crises).
[20] Have a family or personal history of multiple endocrine neoplasia
type 2 (MEN2) or familial medullary thyroid carcinoma (MTC) or personal
history of nonfamilial MTC.
[21] Have a serum calcitonin level at screening of: (based on central
laboratory results)
- =20 ng/L at Visit 1, if eGFR =60 mL/min/1.73 m2, or
- =35 ng/L at Visit 1, if eGFR <60 mL/min/1.73 m2.
[22] Have a history of an active or untreated malignancy or are in
remission from a clinically significant malignancy for less than 5 years.
An exception for this criterion is basal or squamous cell skin cancer, in
situ carcinomas of the cervix, or in situ prostate cancer.
[23] Have a history of any other condition (such as known drug or
alcohol abuse or psychiatric disorder) that, in the opinion of the
investigator, may preclude the patient from following and completing the
protocol.
[24] Have had a transplanted organ (corneal transplants [keratoplasty]
allowed) or awaiting an organ transplant.
[25] Have any other condition (eg, hypersensitivity) that is a
contraindication to any incretin or GLP-1 RAs.
[26] Have had an MI, surgical or percutaneous coronary
revascularization procedure, ischemic stroke, carotid stenting or surgical
revascularization, nontraumatic amputation or peripheral vascular
procedure (eg, stenting or surgical revascularization) less than 60 days
prior to screening.
[27] Have had coronary artery bypass graft surgery less than 5 years
prior to Screening.
[28] Treatment with any incretin, GLP-1 RA, or pramlintide in a period of
3 months prior to Visit 1.
[29] Discontinuation of any incretin, GLP-1 RA, or pramlintide due to
intolerab
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method